Bank of New York Mellon’s Keryx Biopharmaceuticals Inc KERX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2018
Q4 | – | Sell |
-987,204
| Closed | -$3.36M | – | 4323 |
|
|
2018
Q3 | $3.36M | Sell |
987,204
-69,607
| -7% | -$251K | ﹤0.01% | 2581 |
|
|
2018
Q2 | $3.97M | Buy |
1,056,811
+102,014
| +11% | +$497K | ﹤0.01% | 2508 |
|
|
2018
Q1 | $3.9M | Buy |
954,797
+10,934
| +1% | +$50.9K | ﹤0.01% | 2477 |
|
|
2017
Q4 | $4.39M | Sell |
943,863
-29,366
| -3% | -$162K | ﹤0.01% | 2419 |
|
|
2017
Q3 | $6.91M | Buy |
973,229
+10,175
| +1% | +$73.2K | ﹤0.01% | 2182 |
|
|
2017
Q2 | $6.96M | Buy |
963,054
+32,687
| +4% | +$204K | ﹤0.01% | 2156 |
|
|
2017
Q1 | $5.73M | Sell |
930,367
-455,019
| -33% | -$2.49M | ﹤0.01% | 2264 |
|
|
2016
Q4 | $8.12M | Buy |
1,385,386
+270,318
| +24% | +$1.48M | ﹤0.01% | 2065 |
|
|
2016
Q3 | $5.92M | Buy |
1,115,068
+169,936
| +18% | +$916K | ﹤0.01% | 2152 |
|
|
2016
Q2 | $6.26M | Sell |
945,132
-67,230
| -7% | -$376K | ﹤0.01% | 2091 |
|
|
2016
Q1 | $4.73M | Sell |
1,012,362
-8,614
| -0.8% | -$34.4K | ﹤0.01% | 2208 |
|
|
2015
Q4 | $5.16M | Buy |
1,020,976
+50,035
| +5% | +$238K | ﹤0.01% | 2198 |
|
|
2015
Q3 | $3.42M | Sell |
970,941
-128,864
| -12% | -$863K | ﹤0.01% | 2435 |
|
|
2015
Q2 | $11M | Buy |
1,099,805
+144,366
| +15% | +$1.55M | ﹤0.01% | 1918 |
|
|
2015
Q1 | $12.2M | Buy |
955,439
+180,764
| +23% | +$2.32M | ﹤0.01% | 1841 |
|
|
2014
Q4 | $11M | Buy |
774,675
+20,435
| +3% | +$317K | ﹤0.01% | 1862 |
|
|
2014
Q3 | $10.4M | Buy |
754,240
+241,470
| +47% | +$3.7M | ﹤0.01% | 1875 |
|
|
2014
Q2 | $7.89M | Sell |
512,770
-22,162
| -4% | -$314K | ﹤0.01% | 2068 |
|
|
2014
Q1 | $9.12M | Buy |
534,932
+40,192
| +8% | +$606K | ﹤0.01% | 1957 |
|
|
2013
Q4 | $6.41M | Buy |
494,740
+5,201
| +1% | +$62.1K | ﹤0.01% | 2148 |
|
|
2013
Q3 | $4.94M | Buy |
489,539
+31,263
| +7% | +$278K | ﹤0.01% | 2259 |
|
|
2013
Q2 | $3.42M | Buy |
+458,276
| New | +$3.58M | ﹤0.01% | 2419 |
|
Bank of New York Mellon's KERX Position: Q4 2018 in Review
Bank of New York Mellon sold out of Keryx Biopharmaceuticals Inc (KERX) in Q4 2018, closing a stake of 987,204 shares — an estimated $3.36M sold.
Bank of New York Mellon first reported a position in KERX in Q2 2013 and held it in 22 quarters. The position peaked at $12.2M in Q1 2015. 1 fund tracked by Wall St. Rank holds KERX as of Q4 2018.
- Bank of New York Mellon reported no remaining Keryx Biopharmaceuticals Inc position as of Q4 2018 after selling out during the quarter.
- Bank of New York Mellon sold 987,204 Keryx Biopharmaceuticals Inc shares in Q4 2018, an estimated $3.36M.
- Bank of New York Mellon first reported a position in Keryx Biopharmaceuticals Inc in Q2 2013 and held it in 22 quarters.
- Bank of New York Mellon's Keryx Biopharmaceuticals Inc position peaked at $12.2M in Q1 2015.
- 1 fund tracked by Wall St. Rank held Keryx Biopharmaceuticals Inc as of Q4 2018.
Based on Bank of New York Mellon's 13F filing for Q4 2018, filed 11 Feb 2019.